Pfizer Presses FDA To Revise Combo Drug Exclusivity Policy For Duavee
Executive Summary
Citizen petition seeks five-year NCE exclusivity for Pfizer’s estrogen/bazedoxifene combo after district court tells FDA its inconsistent position is unreasonable.
You may also be interested in...
Ferring Wins In Combo Exclusivity Case; FDA Lacks 'Legitimate Reason' To Reject
Court finds FDA erred in not giving the fixed-dose combo product Prepopik five years of market exclusivity since it had awarded the exclusivity to similarly situated single-entity drug products.
All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective
FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.